NASDAQ$TNDM

Tandem Diabetes Care Inc · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Achieved record quarterly sales and increased full-year sales guidance.

Tandem Diabetes Care reported a successful third quarter in 2024, achieving the highest quarterly sales in the company's history. Worldwide GAAP sales increased by 31% to $244.0 million compared to Q3 2023. The company also demonstrated positive Adjusted EBITDA and a return to positive free cash flow, leading to an increase in full year 2024 sales guidance.

  • Worldwide GAAP sales increased 31 percent to $244.0 million compared to third quarter 2023.
  • Grew worldwide pump shipments by more than 25 percent compared to third quarter 2023.
  • Achieved year-over-year growth in new pump starts in the United States, including growth in new customers starting from multiple daily injections.
  • Demonstrated positive Adjusted EBITDA and a return to positive free cash flow.

Headline financials

Total Revenue

$244M

Previous: $186M+31.4%
EPS

-$0.35

Previous: -$0.38+7.9%
Adjusted EBITDA

$4.03M

No prior period
GAAP Gross Margin

51.0%

No prior period
Non-GAAP Gross Margin

51.0%

No prior period
GAAP Operating Margin

-11.0%

No prior period
Non-GAAP Operating Margin

-11.0%

No prior period
Capital Expenditures

-$16.2M

Previous: -$21.6M+25.2%
Free Cash Flow

-$39.4M

Previous: -$54.6M+27.8%
Net Income

-$23.3M

Previous: -$33M+29.5%
Operating Income

-$26.1M

Previous: -$31.5M+17.3%
Gross Profit

$125M

Previous: $89.8M+38.9%
Cash & Equivalents

$49M

Previous: $79.6M-38.4%
Total Assets

$958M

Previous: $940M+1.9%
R&D Expense

$51.1M

Previous: $42M+21.8%
Stock-Based Comp

$26.3M

Previous: $20.7M+26.7%

Revenue & EPS history

Tandem Diabetes · Revenue · Quarterly

$244M

Q3 2024+31.4%vs Q3 2023
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Tandem Diabetes · $80.7M total across 1 segment · Q3 2022

  • Pump Sales
    $80.7M

Forward guidance

The Company is increasing 2024 sales guidance and reaffirming other financial guidance as follows:

Tailwinds

  • Non-GAAP sales are estimated to be approximately $903 million to $910 million for the full year.
  • Sales in the United States of $645 million to $650 million.
  • Sales outside the United States of approximately $258 million to $260 million.
  • Non-GAAP gross margin is estimated to be approximately 51 percent.
  • Adjusted EBITDA margin is estimated to be breakeven as a percent of sales.

Headwinds

  • Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $120 million.
  • Approximately $100 million non-cash, stock-based compensation expense.
  • Approximately $20 million depreciation and amortization expense.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

-0.4%

Avg return

Earnings day

-2.2%

Avg return

5 days after

+3.5%

Avg return

30 days after

55%

27 / 49 earnings

Positive

+32.8%

Q4 2025

Best reaction

-63.6%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+7.6%-23.6%+5.0%
Q4 2025+32.8%+40.4%+34.0%
Q3 2025+22.0%+35.5%+56.9%
Q1 2025+18.6%+26.5%+17.6%
Q4 2024-35.2%-42.0%-42.6%
Q3 2024+0.6%-5.3%-9.1%
Q2 2024+12.7%+17.3%+17.6%
Q1 2024+23.5%+21.5%+41.5%
Q4 2023+6.1%+22.5%+28.4%
Q3 2023-12.1%-11.5%+22.5%
Q2 2023+2.8%-13.4%-14.3%
Q1 2023-2.9%-13.4%-35.9%
Q4 2022-2.1%-8.0%+8.0%
Q3 2022-34.3%-31.5%-23.7%
Q2 2022-14.0%-11.8%-34.3%
Q1 2022-16.4%-27.6%-33.8%
Q4 2021-0.3%+7.6%+7.6%
Q3 2021-4.9%-2.6%-4.3%
Q2 2021+4.7%+2.6%+8.8%
Q1 2021-5.6%-11.9%-5.8%
Q4 2020+3.5%+4.4%-10.0%
Q3 2020+1.5%-11.4%-17.9%
Q2 2020+1.8%+3.0%+10.1%
Q1 2020+7.6%+13.7%+11.5%
Q4 2019-11.4%-15.2%-34.7%
Q3 2019-6.5%-8.0%+2.2%
Q2 2019+2.9%-1.5%+14.2%
Q1 2019-5.8%+6.3%+9.2%
Q4 2018+27.9%+43.2%+31.8%
Q3 2018+6.3%-2.2%-2.1%
Q2 2018+7.7%+29.0%+59.9%
Q1 2018+7.9%+7.7%+96.4%
Q4 2017+23.1%+25.0%+57.0%
Q3 2017-3.4%-6.4%+2.7%
Q2 2017-17.3%-39.4%+8.7%
Q1 2017-11.8%-10.5%-22.4%
Q4 2016-19.1%-10.6%-51.1%
Q3 2016-63.6%-66.9%-63.2%
Q2 2016-13.9%-18.8%-8.4%
Q1 2016+7.1%
Q4 2015+11.9%
Q3 2015+20.6%
Q2 2015+8.9%
Q1 2015+1.7%
Q4 2014-3.1%
Q3 2014-11.0%
Q2 2014+11.4%
Q1 2014-11.7%
Q4 2013+4.0%
Q2 2013
Q1 2013
Q4 2012
Q3 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro